Once-weekly Exenatide vs. Sitagliptin or Pioglitazone

Once-weekly Exenatide vs. Sitagliptin or Pioglitazone: Long-acting exenatide lowered glycosylated hemoglobin levels more than the other two drugs did. After 26 weeks, exenatide lowered the mean HbA1c level significantly more than either sitagliptin or pioglitazone (–1.5% vs. –0.9% and –1.2%). Patients who received exenatide also lost significantly more weight than those who took the other two agents (–2.3 kg vs. –0.8 kg and +2.8 kg). No major hypoglycemic episodes were reported. In an earlier trial (JW Gen Med Jul 13 2010), once-weekly exenatide was superior to daily insulin glargine for short-term glycemic control and weight loss. The Lancet 2010 Aug 7; 376:431